179 related articles for article (PubMed ID: 23248118)
1. Application of a proapoptotic peptide to intratumorally spreading cancer therapy.
Chen R; Braun GB; Luo X; Sugahara KN; Teesalu T; Ruoslahti E
Cancer Res; 2013 Feb; 73(4):1352-61. PubMed ID: 23248118
[TBL] [Abstract][Full Text] [Related]
2. The anoikis effector Bit1 displays tumor suppressive function in lung cancer cells.
Yao X; Jennings S; Ireland SK; Pham T; Temple B; Davis M; Chen R; Davenport I; Biliran H
PLoS One; 2014; 9(7):e101564. PubMed ID: 25003198
[TBL] [Abstract][Full Text] [Related]
3. TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells.
Brunquell C; Biliran H; Jennings S; Ireland SK; Chen R; Ruoslahti E
Mol Cancer Res; 2012 Nov; 10(11):1482-95. PubMed ID: 22952044
[TBL] [Abstract][Full Text] [Related]
4. Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy.
Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
Oncol Rep; 2017 Apr; 37(4):2063-2070. PubMed ID: 28260064
[TBL] [Abstract][Full Text] [Related]
5. Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway.
Fan T; Chen J; Zhang L; Gao P; Hui Y; Xu P; Zhang X; Liu H
Mol Cancer; 2016 Mar; 15():23. PubMed ID: 26956728
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase D is a positive regulator of Bit1 apoptotic function.
Biliran H; Jan Y; Chen R; Pasquale EB; Ruoslahti E
J Biol Chem; 2008 Oct; 283(42):28029-37. PubMed ID: 18703509
[TBL] [Abstract][Full Text] [Related]
7. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
8. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
[TBL] [Abstract][Full Text] [Related]
9. sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment.
Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
Sci Rep; 2017 Apr; 7(1):579. PubMed ID: 28373646
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Bit1 expression promotes growth, anoikis resistance, and transformation of immortalized human bronchial epithelial cells via Erk activation-dependent suppression of E-cadherin.
Yao X; Gray S; Pham T; Delgardo M; Nguyen A; Do S; Ireland SK; Chen R; Abdel-Mageed AB; Biliran H
Biochem Biophys Res Commun; 2018 Jan; 495(1):1240-1248. PubMed ID: 29170133
[TBL] [Abstract][Full Text] [Related]
11. Anoikis effector Bit1 negatively regulates Erk activity.
Kairouz-Wahbe R; Biliran H; Luo X; Khor I; Wankell M; Besch-Williford C; Pascual J; Oshima R; Ruoslahti E
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1528-32. PubMed ID: 18218778
[TBL] [Abstract][Full Text] [Related]
12. Bit1 in anoikis resistance and tumor metastasis.
Jenning S; Pham T; Ireland SK; Ruoslahti E; Biliran H
Cancer Lett; 2013 Jun; 333(2):147-51. PubMed ID: 23376255
[TBL] [Abstract][Full Text] [Related]
13. Metastasis of tumor cells is enhanced by downregulation of Bit1.
Karmali PP; Brunquell C; Tram H; Ireland SK; Ruoslahti E; Biliran H
PLoS One; 2011; 6(8):e23840. PubMed ID: 21886829
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies against human bit1, an apoptosis-associated mitochondrial protein.
Hua W; Chen B; Zhang W; Miao S; Zhang H; Xin X
Hybridoma (Larchmt); 2009 Jun; 28(3):167-71. PubMed ID: 19519243
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
Hu C; Chen X; Huang Y; Chen Y
Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
[TBL] [Abstract][Full Text] [Related]
16. The Anoikis Effector Bit1 Inhibits EMT through Attenuation of TLE1-Mediated Repression of E-Cadherin in Lung Cancer Cells.
Yao X; Pham T; Temple B; Gray S; Cannon C; Chen R; Abdel-Mageed AB; Biliran H
PLoS One; 2016; 11(9):e0163228. PubMed ID: 27655370
[TBL] [Abstract][Full Text] [Related]
17. Pathological implication and function of Bcl2-inhibitor of transcription in ovarian serous papillary adenocarcinomas.
Hua W; Miao S; Zou W; Yang H; Chen BL
Neoplasma; 2013; 60(2):143-50. PubMed ID: 23259782
[TBL] [Abstract][Full Text] [Related]
18. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
[TBL] [Abstract][Full Text] [Related]
19. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
Lingasamy P; Laarmann AH; Teesalu T
Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
[TBL] [Abstract][Full Text] [Related]
20. Induction of Anoikis following myoblast transplantation into SCID mouse muscles requires the Bit1 and FADD pathways.
Bouchentouf M; Benabdallah BF; Rousseau J; Schwartz LM; Tremblay JP
Am J Transplant; 2007 Jun; 7(6):1491-505. PubMed ID: 17511679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
